EU panel rejects Pfizer's tanezumab for osteoarthritis pain

Any lingering hope that Pfizer may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor tanezumab looks to have been dashed after the EMA's human medicines committe

Thumbs-down from FDA experts for Pfizer/Lilly's painkiller t...

After more than a decade of fraught clinical development it looks like the end of the line for Pfizer/Lilly painkiller tanezumab, which promised to be an alternative to addictive opioid pai

FDA starts review of Pfizer, Lilly’s non-opioid painkiller

Pfizer/Lilly non-opioid pain drug shows more positive result...

Results from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can be effective in osteoarthritis in higher doses, but lower doses remain ineffective and the dr

More positive results for Pfizer/Lilly’s non-opioid pain dru...

Pfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain drug tanezumab, this time in chronic lower back pain (CBLP).